Coronavirus pandemic disease (COVID-19) is caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). At the time of this paper writing, over 2, 5 million …

In their review of the evidence base for emergency use authorizations (EUAs) by the US
Food and Drug Administration (FDA), 1 the authors assert that “The presence of EUAs may …

Resumen En diciembre 2019, en Wuhan, China, se registró un aumento inusual de casos
de infección respiratoria aguda de rápida progresión y alta letalidad. Al poco tiempo es …

Introducción: durante la pandemia de" gripe española" de 1918, se introdujo el uso de
plasma obtenido de individuos convalecientes como posible tratamiento para los pacientes …

Background Convalescent plasma is frequently administered to patients with Covid-19 and
has been reported, largely on the basis of observational data, to improve clinical outcomes …

In this issue of JAMA, Shen et al report findings from a preliminary study of 5 severely ill
patients with coronavirus disease 2019 (COVID-19) who were treated in the Shenzhen Third …

The use of plasma from patients who have recovered from viral infections was used for the
first time back in the 20th century to treat cases of the so-called Spanish flu 1. More recently …

Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

Importance The evidence for benefit of convalescent plasma for critically ill patients with
COVID-19 is inconclusive. Objective To determine whether convalescent plasma would …